TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04171167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: three visits: 0, after washout, after FP usage
Study: NCT00074152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Given within 10 weeks after surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given within 6 months after surgery
Study: NCT04171167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: three visits: 0, after washout, after FP usage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: three visits: 0, after washout, after FP usage
Study: NCT03780985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device insertion
Description: Post-placental insertion of intrauterine device during Cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device insertion
Description: Post-placental insertion of intrauterine device during Cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: to delivery of the fetus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: to delivery of the fetus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: to fix the intrauterine device
Study: NCT03696849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished emax Press
Description: lithium disilicate glass ceramic crowns subjected to polishing only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: polished emax Press
Description: lithium disilicate glass ceramic crowns subjected to polishing only
Study: NCT00054756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRH (Thyrotropin Releasing Hormone)
Study: NCT04601181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART22 cells injection
Description: Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study
Study: NCT02147691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid 15%
Description: Applied to the face each AM and PM
Study: NCT00094861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study: NCT01534741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dialyzer comparison
Description: Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialyzer
Description: Comparison Dialyzer FX60 versus Cordiax60

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialyzer
Description: Comparison Dialyzer FX60 versus Cordiax60
Study: NCT00094861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03560232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/sulbactam
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: See arm description
Study: NCT03003624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colorado® microdissection needle
Description: The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cautery tip
Description: Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP blade
Description: Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
Study: NCT03434496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait Trainer 3
Description: With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Trainer 3
Description: With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
Study: NCT02109601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive bedside training for accessing patient portal
Description: EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited bedside training on patient portal use.
Description: EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
Study: NCT03862963

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of diabetes care
Description: The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
Study: NCT04059042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Participants will have pain threshold testing while listening to silence, music, or nature sounds.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music Listening
Description: Participants will have pain threshold testing while listening to silence, music, or nature sounds.
Study: NCT04255979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Study: NCT03746613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARO
Description: Robotic system for otological procedures
Study: NCT04121546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecare Intervention
Description: Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
Study: NCT00094861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study: NCT04570462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia Via Cooling Machine- Arctic Sun 5000
Description: Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject.
Study: NCT01735955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
Study: NCT02382055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
Study: NCT00787969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Give IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Description: Give IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Give IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Give SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT04169256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYR-PB21
Description: HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
Study: NCT02755805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Study: NCT04024176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
Study: NCT02316301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long interval misoprostol
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short interval misoprostol
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT04816175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquire Therapy
Description: This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
Study: NCT01125254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg po for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: 5mg po for 12 months
Study: NCT03754036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep manipulation
Description: Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep manipulation
Description: Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
Study: NCT02382055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Behavioral Treatment
Description: Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Behavioral Treatment
Description: Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
Study: NCT02845141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse
Description: bone tunnel filled with Actifuse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone graft
Description: bone graft to fill bone tunnel
Study: NCT02556983

Intervention type: RADIATION
Intervention: CT
Description: Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
Study: NCT02804711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
Study: NCT02147691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33%
Description: Applied to the face each AM 30 minutes after the application of Azelaic acid 15%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.33%
Description: Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
Study: NCT01548209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
Study: NCT04430699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of care radiation therapy 1x daily up to 8 weeks.